Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $260.0 million dollar outflow -- that's a 6.0% decrease week over week (from 51,250,000 to 48,150,000). Among the largest underlying components of IXJ, in trading today CVS Health Corporation (Symbol: CVS) is up about 1.3%, Cigna Corp (Symbol: CI) is up about 0.1%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is higher by about 0.1%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average:
Looking at the chart above, IXJ's low point in its 52 week range is $74.50 per share, with $91.7799 as the 52 week high point — that compares with a last trade of $84.25. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
PGJ shares outstanding history
Institutional Holders of ATW
State Street MACD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

iShares Global Healthcare ETF Experiences Big Outflow

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 (Symbol: VONE) where we have detected an approximate $202.5 million dollar outflow -- that's a 2.7% decrease week over week (from 23,965,000 to 23,320,000). Among the largest underlying components of VONE, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 1.6%, Merck & Co Inc (Symbol: MRK) is up about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2.7%. For a complete list of holdings, visit the VONE Holdings page » The chart below shows the one year price performance of VONE, versus its 200 day moving average:
Looking at the chart above, VONE's low point in its 52 week range is $218.75 per share, with $316.38 as the 52 week high point — that compares with a last trade of $314.58. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
TRPX market cap history
Top Ten Hedge Funds Holding IFRA
Top Ten Hedge Funds Holding INDI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

VONE, UNH, MRK, TMO: ETF Outflow Alert

(RTTNews) - Thermo Fisher Scientific Inc. (TMO), a life science and clinical research company, on Tuesday announced it has priced a $3.8 billion senior notes offering to partially fund its pending acquisition of Clario Holdings, Inc.
Thermo Fisher expects the offering to close on or about February 12.
The offering comprises $1.0 billion of 4.215% senior notes due 2031 priced at par, $750 million of 4.550% senior notes due 2033 priced at 99.783%, $1.3 billion of 4.902% senior notes due 2036 priced at par, and $750 million of 5.546% senior notes due 2046 priced at par.
Interest on the notes will be paid on a semi-annual basis.
Net proceeds will be used to pay a portion of the cash for the Clario acquisition.
The company said that, pending the completion of the transaction, proceeds may also be used for general corporate purposes, including acquisitions, debt repayment or refinancing, working capital, capital expenditures, share repurchases, or short-term investments.
Thermo Fisher Scientific closed the regular trading session on February 10, at $546.76, up $3.93 or 0.72%. Later, in overnight trading, the share price rose to $549, gaining $2.24 or 0.41%, as of 12:18 AM EST.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Prices $3.8 Bln Senior Notes To Fund Clario Acquisition

Key Points
Corporate spending on AI doesn't show signs of slowing anytime soon.
Nvidia is widening its competitive lead in the AI market with its investment in advanced computing systems.
Shares of Nvidia (NASDAQ: NVDA) are up about 47% over the past year. The current cycle of spending on chips and data centers, which has benefited Nvidia in recent years, doesn't appear to be slowing anytime soon.
Google parent Alphabet just said it will spend at least $175 billion in capital expenditures this year to support demand for artificial intelligence (AI).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
However, Nvidia is not entirely reliant on selling powerful chips to AI hyperscalers, including Google. Nvidia has an opportunity to expand its market potential by delivering advanced computing systems to other industries that may undervalue its future growth.
The World Health Organization expects a shortage of millions of healthcare providers by 2030, and Nvidia is providing the computing backbone that could help fill that gap. It's partnering with Thermo Fisher Scientific to build an AI lab computing system powered by its DGX Spark supercomputer. This lays the groundwork for agentic AI systems to autonomously run experiments and complete other lab work.
This positions Nvidia to gain a foothold in the life sciences industry, which spends about $300 billion annually on research and development.
Nvidia is not just a chip supplier. It's a systems and solutions provider. This further differentiates Nvidia from custom chip designers like Broadcom that some investors see as a threat to Nvidia's AI chip dominance. Nvidia is helping enterprises solve complex problems, which makes it an indispensable partner.
For investors, that matters because the stock's valuation looks attractive, trading at 24 times this year's consensus earnings estimate. That's a steal, with Wall Street analysts expecting Nvidia's earnings to climb 57% this year. The recent dip could provide an excellent buying opportunity before the stock surges to new highs later this year.
Should you buy stock in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,299!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,136,601!*
Now, it’s worth noting Stock Advisor’s total average return is 914% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 9, 2026.
John Ballard has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Nvidia, and Thermo Fisher Scientific. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This Top Artificial Intelligence (AI) Stock Could Have More Upside in 2026

Key Points
Increased MELI stake by 44,747 shares; estimated transaction value of $93.99 million based on quarterly average pricing.
Quarter-end position value rose by $87.34 million, reflecting both trading activity and stock price movement.
Estimated trade equaled 1.64% of C WorldWide Group's reportable U.S. equity assets under management.
Post-trade holdings: 53,411 shares valued at $107.58 million.
MELI now represents 1.88% of fund AUM, which places it outside the fund's top five holdings.
C WorldWide Group Holding A/S bought increased its stake in MercadoLibre (NASDAQ:MELI), according to a February 04, 2026, SEC filing.
What happened
According to a filing with the Securities and Exchange Commission dated February 04, 2026, C WorldWide Group Holding A/S purchased 44,747 additional shares of MercadoLibre during the fourth quarter. The estimated transaction value, calculated using the average closing price for the quarter, is approximately $93.99 million. The fund's quarter-end position value in MercadoLibre increased by $87.34 million, a figure which includes both trading activity and stock price changes.
What else to know
This was a buy; the position now accounts for 1.88% of C WorldWide Group's reportable U.S. equity assets under management
Top five holdings after the filing:
NASDAQ: GOOGL: $496.35 million (8.7% of AUM)
NASDAQ: MSFT: $416.40 million (7.3% of AUM)
NASDAQ: AMZN: $411.73 million (7.2% of AUM)
NYSE: V: $372.59 million (6.5% of AUM)
NYSE: TMO: $369.94 million (6.5% of AUM)
As of February 3, 2026, MercadoLibre shares were priced at $2,099.90
One-year total return: 10.0%; underperformed the S&P 500 by 5.40 percentage points over the same period
Company overview
Price (as of market close 2/3/26)
$2,099.90
Market Capitalization
$106.46 billion
Revenue (TTM)
$26.19 billion
Net Income (TTM)
$2.08 billion
Company snapshot
Offers an integrated suite of e-commerce, fintech, logistics, classifieds, advertising, and digital storefront solutions across Latin America.
Generates revenue primarily through transaction fees, payment processing, credit products, advertising, logistics services, and value-added marketplace offerings.
Serves businesses, merchants, and individual consumers seeking online commerce, digital payments, credit, and related services in Latin American markets.
MercadoLibre, Inc. is a leading e-commerce and fintech platform in Latin America, operating at scale across multiple countries with a diverse portfolio of digital solutions. The company leverages its integrated ecosystem—including marketplace, payments, credit, and logistics—to drive user engagement and monetize a broad customer base.
What this transaction means for investors
C Worldwide increased its MercadoLibre stake by 517% in Q4. In a sense, its interest in the Latin America conglomerate is not unusual since Amazon is one of the fund’s largest positions.
The retail stock struggled over the last year as its e-commerce markets faced more competition from Amazon and others. Also, its fintech arm Mercado Pago had to massively increase its provision for doubtful accounts, as many of the loans it made remain unpaid.
However, MercadoLibre has employed technology to address the increase in nonperforming loans.
Also, C Worldwide may have seen an opportunity, especially given the rapid improvement in Argentina’s economy, one of MercadoLibre’s largest markets. Moreover, the leadership change in Venezuela after the quarter ended could provide further opportunity for the company.
Finally, the stock’s slow growth has helped make MercadoLibre a cheaper stock. While it may not appear so, given its P/E ratio of 51, that earnings multiple compares well with Amazon in past years, indicating a recovery could come sooner rather than later.
Should you buy stock in MercadoLibre right now?
Before you buy stock in MercadoLibre, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MercadoLibre wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $431,111!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,105,521!*
Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 4, 2026.
Will Healy has positions in MercadoLibre. The Motley Fool has positions in and recommends Alphabet, Amazon, MercadoLibre, Microsoft, Thermo Fisher Scientific, and Visa. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

C WorldWide Group Loads Up 45,000 MercadoLibre Shares Worth $94 Million

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $166.8 million dollar outflow -- that's a 3.6% decrease week over week (from 47,850,000 to 46,150,000). Among the largest underlying components of IXJ, in trading today Merck & Co Inc (Symbol: MRK) is up about 2.4%, UnitedHealth Group Inc (Symbol: UNH) is off about 1.4%, and Thermo Fisher Scientific Inc (Symbol: TMO) is up by about 0.9%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average:
Looking at the chart above, IXJ's low point in its 52 week range is $80.681 per share, with $100.98 as the 52 week high point — that compares with a last trade of $99.35. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Cheap Energy Shares
PKI Options Chain
MNRL Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

IXJ, MRK, UNH, TMO: Large Outflows Detected at ETF

For Immediate Release
Chicago, IL – February 4, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. GOOGL, Apple Inc. AAPL, Thermo Fisher Scientific Inc. TMO and New England Realty Associates Limited Partnership NEN.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Alphabet, Apple and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Apple Inc. and Thermo Fisher Scientific Inc., as well as a micro-cap stock New England Realty Associates Limited Partnership. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Q4 Earnings, JOLTS & a Changing of the Disney Guard
Today's Featured Research Reports
Alphabet's shares have outperformed the Zacks Internet - Services industry over the past six months (+76% vs. +67.2%). The company is benefiting from accelerated growth across AI infrastructure, Google Cloud and Search. Google Cloud ended the third quarter of 2025 with $155 billion in backlog, up 46% sequentially.
The number of new Google Cloud Platform customers increased by roughly 34% year over year, and 70% of Google Cloud customers now use Alphabet's AI products. In third-quarter 2025, revenues from products built on Alphabet's generative AI models (Gemini, Imagen, Veo, Chirp and Lyria) grew more than 200% year-over-year, reflecting accelerating adoption.
Search is benefiting from AI Overviews and AI Mode that has driven growth in overall queries. YouTube is benefiting from the growing demand for shorts. However, stiff competition in cloud computing has been concerning.
(You can read the full research report on Alphabet here >>>)
Shares of Apple have outperformed the Zacks Computer - Micro Computers industry over the past six months (+33.3% vs. +31.5%). The company is benefiting from strong growth in iPhone and Services revenues. AAPL continues to gain momentum in emerging markets: India and Greater China reported strong fiscal first quarter growth, driven by iPhone sales.
Apple now has more than 1 billion paid subscribers across its Services portfolio and 2.5 billion active devices. Expanding capabilities of AI Intelligence is noteworthy. Apple expects the March quarter's net sales to grow between 13% and 16% on a year-over-year basis despite constrained iPhone supplies. Services are expected to grow at the rate of fourth quarter fiscal 2025.
However, gross margin is expected to be 48-49% in the second quarter of fiscal 2026. Increasing regulatory headwinds and stiff competition are major concerns for the iPhone-maker.
(You can read the full research report on Apple here >>>)
Thermo Fisher's shares have outperformed the Zacks Medical - Instruments industry over the past six months (+25.4% vs. +2.1%). The company continues to strengthen its foundation by consistently advancing its growth strategy. Its latest round of innovations supports scientific breakthroughs, advances precision medicine and greater lab productivity for customers.
Thermo Fisher's Bioproduction arm remains a key driver with new facilities and product lines. Strategic acquisitions further enhance its offerings. Per the Zacks Consensus Estimate, TMO's sales may grow 4.6% and 5.1% in 2026 and 2027, respectively, year over year.
Meanwhile, robust solvency further instills optimism about the stock. However, a volatile macroeconomic environment can dent its operations. Currency woes and fierce competitive pressure add to the worry.
(You can read the full research report on Thermo Fisher here >>>)
Shares of New England Realty have underperformed the Zacks Real Estate - Operations industry over the past six months (-6.2% vs. +6.7%). This microcap company with a market capitalization of $180.24 million is facing rising leverage ($511.2 million), net income compression and softening new lease rates introduce caution. A liquidity covenant breach and floating-rate debt add refinancing risk.
Nevertheless, NERA is capitalizing on favorable urbanization and housing supply-demand imbalances in Eastern Massachusetts and Southern New Hampshire, expanding assets by 25% YTD. The Hill Estates acquisition and Mill Street development align with strong demographic and affordability trends.
Rental income rose 9.1% to $65 million, supported by resilient renewal pricing (+5.7%) and high occupancy. Long-term demand fundamentals, including Boston's robust job market and limited new housing starts, enhance rental pricing power and asset appreciation. Strategic use of Chapter 40B programs provides financing advantages.
(You can read the full research report on New England Realty here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights Alphabet, Apple, Thermo Fisher Scientific and New England Realty Associates

Tuesday, February 3, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Apple Inc. (AAPL) and Thermo Fisher Scientific Inc. (TMO), as well as a micro-cap stock New England Realty Associates Limited Partnership (NEN). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Q4 Earnings, JOLTS & a Changing of the Disney Guard
Today's Featured Research Reports
Alphabet’s shares have outperformed the Zacks Internet - Services industry over the past six months (+76% vs. +67.2%). The company is benefiting from accelerated growth across AI infrastructure, Google Cloud and Search. Google Cloud ended the third quarter of 2025 with $155 billion in backlog, up 46% sequentially.
The number of new Google Cloud Platform customers increased by roughly 34% year over year, and 70% of Google Cloud customers now use Alphabet’s AI products. In third-quarter 2025, revenues from products built on Alphabet’s generative AI models (Gemini, Imagen, Veo, Chirp and Lyria) grew more than 200% year-over-year, reflecting accelerating adoption.
Search is benefiting from AI Overviews and AI Mode that has driven growth in overall queries. YouTube is benefiting from the growing demand for shorts. However, stiff competition in cloud computing has been concerning.
(You can read the full research report on Alphabet here >>>)
Shares of Apple have outperformed the Zacks Computer - Micro Computers industry over the past six months (+33.3% vs. +31.5%). The company is benefiting from strong growth in iPhone and Services revenues. AAPL continues to gain momentum in emerging markets: India and Greater China reported strong fiscal first quarter growth, driven by iPhone sales.
Apple now has more than 1 billion paid subscribers across its Services portfolio and 2.5 billion active devices. Expanding capabilities of AI Intelligence is noteworthy. Apple expects the March quarter’s net sales to grow between 13% and 16% on a year-over-year basis despite constrained iPhone supplies. Services are expected to grow at the rate of fourth quarter fiscal 2025.
However, gross margin is expected to be 48-49% in the second quarter of fiscal 2026. Increasing regulatory headwinds and stiff competition are major concerns for the iPhone-maker.
(You can read the full research report on Apple here >>>)
Thermo Fisher’s shares have outperformed the Zacks Medical - Instruments industry over the past six months (+25.4% vs. +2.1%). The company continues to strengthen its foundation by consistently advancing its growth strategy. Its latest round of innovations supports scientific breakthroughs, advances precision medicine and greater lab productivity for customers.
Thermo Fisher’s Bioproduction arm remains a key driver with new facilities and product lines. Strategic acquisitions further enhance its offerings. Per the Zacks Consensus Estimate, TMO’s sales may grow 4.6% and 5.1% in 2026 and 2027, respectively, year over year.
Meanwhile, robust solvency further instills optimism about the stock. However, a volatile macroeconomic environment can dent its operations. Currency woes and fierce competitive pressure add to the worry.
(You can read the full research report on Thermo Fisher here >>>)
Shares of New England Realty have underperformed the Zacks Real Estate - Operations industry over the past six months (-6.2% vs. +6.7%). This microcap company with a market capitalization of $180.24 million is facing rising leverage ($511.2 million), net income compression and softening new lease rates introduce caution. A liquidity covenant breach and floating-rate debt add refinancing risk.
Nevertheless, NERA is capitalizing on favorable urbanization and housing supply-demand imbalances in Eastern Massachusetts and Southern New Hampshire, expanding assets by 25% YTD. The Hill Estates acquisition and Mill Street development align with strong demographic and affordability trends.
Rental income rose 9.1% to $65 million, supported by resilient renewal pricing (+5.7%) and high occupancy. Long-term demand fundamentals, including Boston’s robust job market and limited new housing starts, enhance rental pricing power and asset appreciation. Strategic use of Chapter 40B programs provides financing advantages.
(You can read the full research report on New England Realty here >>>)
Other noteworthy reports we are featuring today include The Boeing Co. (BA), Western Digital Corp. (WDC) and Nasdaq, Inc. (NDAQ).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Increasing Defense Orders Drive Boeing (BA), Amid Labor Shortage
Per the Zacks analyst, Boeing is likely to benefit from increasing orders from the U.S. government for its defense systems. Yet labor shortage result in delays and likely impact operating results.
Western Digital (WDC) Poised for Growth on AI Storage and HDD Demand
Per the Zacks analyst, Western Digital's performance is being driven by higher demand for cloud end market and Agentic AI. It has formulated strategies to tackle macro and geopolitical woes.
Accelerating Non-Trading Revenue Base Aids Nasdaq (NDAQ)
Per the Zacks analyst, Nasdaq is set to grow on its focus toward Market Technology and Information Services businesses. However, increasing expenses weighing on margin expansion is likely a concern.
Las Vegas Sands (LVS) Bets on Strategic Efforts, High Competition Ail
Per the Zacks analyst, Las Vegas Sands' focus on property reinvestments, shareholder returns and strong Marina Bay Sands performance bode well. Yet competitive market dynamics and high costs ail.
Repligen's (RGEN) Product Portfolio Aids Sales Amid Stiff Rivalry
Per the Zacks analyst, Repligen's product franchisees are generating significant revenues owing to continued demand. Stiff competition in the bioprocessing products market remains an overhang.
Group 1 Automotive (GPI) Expansion Helps, Margins Under Pressure
Per the Zacks analyst, Group 1 Automotive benefits from expansion through dealership acquisitions, but rising vehicle prices and margin pressure continue to restrain demand.
Rising Bill Rates and Improving FCF Aid Robert Half (RHI)
Per the Zacks analyst, rising contract talent solutions bill rates show Robert Half's pivot towards high-demand non-discretionary roles. Rising free cash flow (FCF) reflects operational strength.
New Upgrades
Kimberly-Clark (KMB) Benefits from Solid Organic Sales
Per the Zacks analyst, Kimberly-Clark has been benefiting from improved volume-and-mix trends. Volume-plus-mix contributed 3% to organic sales growth in fourth-quarter 2025.
Business Expansion Efforts, Loan Growth to Aid Hancock Whitney (HWC)
Per the Zacks analyst, Hancock Whitney's investments in growth and new markets along with robust loan growth will aid the top line. Its efficient capital distributions reflect a solid balance sheet.
Business Expansion and Solid Liquidity Position Aid TCBI
Per the Zacks analyst, Texas Capital's expansion across corporate banking, healthcare lending and investment banking drives growth. A strong liquidity level aids its capital distribution activities.
New Downgrades
Ovintiv (OVV) Faces Financial Pressure from High Capex Levels
The Zacks analyst believes that Ovintiv's high capex needs are limiting free cash flow, increasing vulnerability to inflation and operational inefficiencies, which could hurt future growth.
Tractor Supply (TSCO) Hurt By Higher Costs and Soft Discretionary Item
Per the Zacks analyst, Tractor Supply is grappling with higher expenses for a while. The company's certain discretionary product lines have been experiencing soft demand and hurting sales.
Low Subscribers, Residential Video Sales Hurts Charter (CHTR)
Per the Zacks analyst, decline in total residential and SMB Internet customers and decline in video customers hurts top-line growth despite strength in advertising sales revenues.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Analyst Reports for Alphabet, Apple & Thermo Fisher

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Thermo Fisher (TMO) Q4 2025 Earnings Transcript

Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57 beat the Zacks Consensus Estimate by 2.1%. The figure increased 7.7% year over year.
The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs.
Fourth-quarter GAAP EPS was $5.21, up 9% when compared with the year-ago quarter’s figure.
Full-year adjusted EPS of $22.87 beat the Zacks Consensus Estimate by 0.6%. The figure increased 4.6% year over year.
TMO’s Revenues
Revenues increased 7.1% year over year to $12.22 billion. The top line surpassed the Zacks Consensus Estimate by 2.3%. Organic revenues in the reported quarter increased 3% year over year.
Full-year revenues increased 3.9% year over year to $44.56 billion. The figure surpassed the Zacks Consensus Estimate by 0.6%.
Following the earnings announcement, shares of TMO rose 0.6% in pre-market trading today.
Thermo Fisher’s Q4 Segmental Analysis
Thermo Fisher operates under four business segments, as discussed below:
Life Sciences Solutions
Revenues in the Life Sciences Solutions segment (24.1% of total revenues) increased 13.5% year over year to $2.95 billion.
Analytical Instruments
Revenues in this segment (18.1%) rose 1.4% year over year to $2.22 billion.
Specialty Diagnostics
Revenues in the Specialty Diagnostics segment (10%) increased 5.2% year over year to $1.22 billion.
Laboratory Products and Biopharma Services
Revenues in this segment (52.2%) rose 7.4% year over year to $6.38 billion.
TMO’s Margin Performance
The gross margin of 41.5% in the fourth quarter contracted 150 basis points (bps) year over year due to a 10% rise in the cost of revenues.
In the quarter, selling, general and administrative expenses rose 7.1% to $1.98 billion. Research and development expenses amounted to $357 million, down 4.5% year over year.
The adjusted operating margin in the quarter was 22.4%, reflecting a contraction of 113 bps.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
TMO’s Financial Position
The company ended the fourth quarter of 2025 with cash and cash equivalents and short-term investments of $10.11 billion compared with $3.55 billion at the end of the third quarter.
Cumulative net cash from operating activities at the end of the fourth quarter was $7.82 billion compared with $8.67 billion a year ago.
Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth of 12.98%.
Our Take on Thermo Fisher Stock
Thermo Fisher exited the fourth quarter of 2025 on a solid note, with both earnings and revenues beating respective estimates. The strong operational performance reflected the effectiveness of the company's proven growth strategy, the PPI Business System and ongoing active management.
Thermo Fisher made several high-impact launches in the fourth quarter, including the Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope. Additionally, the company received FDA approval for the Ion Torrent Oncomine Dx Target Test and the EXENT System. All these developments are poised to support its growth in the coming quarters.
However, the contraction of both margins is discouraging.
TMO’s Zacks Rank & Key Picks
Thermo Fisher currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are National Vision EYE, Boston Scientific BSX and Prestige Consumer Healthcare PBH.
National Vision, currently carrying a Zacks Rank #1 (Strong Buy), reported third-quarter 2025 adjusted EPS of 13 cents, which topped the Zacks Consensus Estimate by 8.3%. Revenues of $487.3 million beat the Zacks Consensus Estimate by 2.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
EYE’s earnings yield of 5.8% compares favorably with the industry’s 2.8% yield. The company beat on earnings in each of the trailing four quarters, with the average surprise being 2.75%.
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2025 adjusted EPS of 75 cents, which exceeded the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion surpassed the Zacks Consensus Estimate by 1.9%.
BSX has an earnings yield of 3.7% compared with the industry’s 2.3% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 7.4%.
Prestige Consumer Healthcare, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 EPS of $1.07, which surpassed the Zacks Consensus Estimate by 10.3%. Revenues of $274.1 million topped the Zacks Consensus Estimate by 6.9%.
PBH has an earnings yield of 7.1% compared with the industry’s 2.8% yield. The company’s earnings outperformed estimates in three of the trailing four quarters and missed in the other one, with the average surprise being 2.8%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	35.13 22.12
Price/Sales	5.28 3.02
P/B	4.48 2.26
P/FCF	37.56 19.94

Indicator	TTM Median
ROE	13.11 24.62
ROA	6.56 6.12
ROI	8.07 9.89
Net Worth	229.83 0.21
Quick Ratio	1.11 1.73
Current Ratio	1.50 2.81

Indicator	TTM Median
Net Profit Margin	15.02 11.00
Operating Margin	17.17 14.17
Gross Margin	41.27 68.95
Return on tangible equity	0.00 53.73

Indicator	TTM Median
EPS	6.57 0.37
EPS Forecast	6.43 0.37
Revenue	11.12B 17.00M
Gross Profit	4.58B —
EBITDA	2.60B —

Thermo Fisher Scientific Inc

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue